CERo Therapeutics has reported encouraging data from a Phase I trial evaluating a treatment for haematologic malignancies in acute myeloid leukaemia (AML). 

In the CERTAIN-T trial, a patient with multiple refractory AML – who had not previously achieved disease control sufficient to enable allogeneic stem cell transplantation – showed 7% bone marrow blast counts on Day 42. 

The patient subsequently underwent allogeneic stem cell transplantation on Day 71 following infusion. 

Allogeneic stem cell transplantation is considered a potentially curative therapeutic option for eligible patients with refractory haematologic malignancies and remains a critical component of treatment for many patients with relapsed or treatment-resistant disease. 

CERo says these observations are preliminary, based on a limited number of patients, and no definitive conclusions regarding safety or efficacy can be made at this stage of the trial. 

“We continue to observe encouraging findings from the ongoing trial, with investigators reporting clinical improvement in two patients treated across the first two cohorts,” said Chris Ehrlich, CEO of CERo. 

“Although formal response assessments remain ongoing, investigators have reported findings suggestive of clinical benefit following treatment with CER-1236. We look forward to continuing dose escalation and further evaluating CER-1236 in the ongoing Phase I study.” 

After treating six patients in the ongoing Phase I trial, CERo has initiated the third planned cohort of the CERTAIN-T study, which is expected to evaluate the planned one billion cells/patient protocol and is currently screening patients for enrolment.